A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia.

ABSTRACT: As more clinically-relevant genomic features of myeloid malignancies are revealed, it has become clear that targeted clinical genetic testing is inadequate for risk stratification. Here, we develop and validate a clinical transcriptome-based assay for stratification of acute myeloid leukemia (AML). Comparison of ribonucleic acid sequencing (RNA-Seq) to whole genome and exome sequencing reveals that a standalone RNA-Seq assay offers the greatest diagnostic return, enabling identification of expressed gene fusions, single nucleotide and short insertion/deletion variants, and whole-transcriptome expression information. Expression data from 154 AML patients are used to develop a novel AML prognostic score, which is strongly associated with patient outcomes across 620 patients from three indepe

SUBMITTER: Docking TR 

PROVIDER: S-EPMC8087683 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature